Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORM-12741 for cold-induced vasospasm in Raynaud's phenomenon secondary to systemic sclerosis
2010-024005-13Phase 2Terminated
- Sponsor
- Orion Corporation
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ORM-12741 in Raynaud disease (2 arms), sponsored by Orion Corporation. Primary endpoints: Effect on finger blood flow and Finger temperature response. Started Dec 2010; status: terminated.
02
Drugs
ORM-12741
03
Conditions
Raynaud disease
Beyond the preview
Go deeper on 2010-024005-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024005-13.